SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Grønbæk Kirsten)
 

Search: WFRF:(Grønbæk Kirsten) > (2016) > Lenalidomide-bendam...

  • Albertsson-Lindblad, AlexandraLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital (author)

Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • American Society of Hematology,2016
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:6814bc18-aa01-4ffd-b682-e1da5f3ca0c9
  • https://lup.lub.lu.se/record/6814bc18-aa01-4ffd-b682-e1da5f3ca0c9URI
  • https://doi.org/10.1182/blood-2016-03-704023DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter open-label phase I/II trial we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment to elderly MCL patients. Patients >65 years with untreated MCL, stage II-IV were eligible for inclusion. Primary endpoints were maximally tolerable dose (MTD) of LEN, and progression-free survival (PFS). Patients received six cycles q4w of L-B-R (L D1-14, B 90 mg/m(2) iv D1-2 and R 375 mg/m(2) iv D1) followed by single LEN (D1-21, q4w, cycles 7-13). 51 patients (median age 71 years) were enrolled 2009-2013. In phase I, the MTD of LEN was defined as 10 mg in cycles 2-6, and omitted in cycle 1. After six cycles, the complete remission rate (CRR) was 64% and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3 year overall survival was 73%. Infection was the most common non-hematological grade 3-5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in three patients; 2 PCP and 1 CMV retinitis. Second primary malignancies (SPM) were observed in eight patients (16%). LEN could safely be combined with R-B, when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs which may limit its use. http://clinicaltrials.gov: NCT00963534.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Kolstad, ArneOslo university hospital (author)
  • Laurell, AnnaUppsala University Hospital(Swepub:lu)onk-ala (author)
  • Räty, RiikkaHelsinki University Central Hospital (author)
  • Grønbæk, KirstenCopenhagen University Hospital (author)
  • Sundberg, JanSkåne University Hospital (author)
  • Pedersen, Lone BredoCopenhagen University Hospital (author)
  • Ralfkiær, ElisabethCopenhagen University Hospital (author)
  • Karjalainen-Lindsberg, Marja-LiisaUniversity of Helsinki,Helsinki University Central Hospital (author)
  • Sundström, ChristerUppsala University (author)
  • Ehinger, MatsLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)efor-meh (author)
  • Geisler, ChristianCopenhagen University Hospital (author)
  • Jerkeman, MatsLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-mje (author)
  • TumörmikromiljöSektion I (creator_code:org_t)

Related titles

  • In:Blood: American Society of Hematology128:14, s. 1814-18201528-00200006-4971

Internet link

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view